(Total Views: 603)
Posted On: 01/08/2025 1:07:04 PM
Post# of 150008
VIR is rocketing up today on news on their first entries into oncology, one to target HER2 on solid tumors and PSMA in prostate cancer.
They are using antibodies as "T-cell engagers" to have their anti-cancer effects. Both seem to have good efficacy and safety.
Once again, using the immune system itself to fight disease more effectively proves to be a winning strategy.
I hope Cytodyn and Leronlimab can step on the gas and be the "firstest with the mostest" in such a competitive field. I wonder what VIR's treatments will cost?
News is here -
https://www.investors.com/news/technology/vir...src=A00220
They are using antibodies as "T-cell engagers" to have their anti-cancer effects. Both seem to have good efficacy and safety.
Once again, using the immune system itself to fight disease more effectively proves to be a winning strategy.
I hope Cytodyn and Leronlimab can step on the gas and be the "firstest with the mostest" in such a competitive field. I wonder what VIR's treatments will cost?
News is here -
https://www.investors.com/news/technology/vir...src=A00220
(6)
(0)Scroll down for more posts ▼
